Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101, a prescription grade Omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Amarin also has next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut with an experienced research and development team. Amarin’s programs capitalize on its lipid science expertise and the known therapeutic benefits of Omega-3 products in treating cardiovascular disease. Amarin has a number of non-core programs for partnering in the area of central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease.
Type
Public
HQ
Dublin, IE
Founded
1991
Employees
210 (est)+6%
Amarin was founded in 1991 and is headquartered in Dublin, IE

Key People at Amarin

Colin Stewart

Colin Stewart

President and CEO
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Executive Chairman and Chief Executive Officer
John Thero

John Thero

CFO
Declan Doogan

Declan Doogan

Chief Medical Officer

Amarin Locations

Dublin, IE
Bedminster Township, US

Amarin Metrics

Amarin Summary

Market capitalization

$781 M

Closing share price

$2.95
Amarin's current market capitalization is $781 M.

Amarin Market Value History

Amarin Company Life

You may also be interested in